Related Experiment Videos
Pharmacotherapy for Alzheimer's disease
P J Whitehouse1, D S Geldmacher
1Alzheimer Center, Case Western Reserve University, Cleveland, Ohio.
Clinics in Geriatric Medicine
|May 1, 1994
Summary
Effective pharmacotherapy for Alzheimer's disease (AD) is a global research priority. Tacrine, a new symptomatic treatment, shows cognitive improvement in some AD patients, with more therapies anticipated.
Area of Science:
- Neurology
- Pharmacology
- Genetics
Background:
- Alzheimer's disease (AD) poses a significant challenge, driving global research for effective treatments.
- Current research focuses on symptomatic therapies and understanding disease pathogenesis.
Purpose of the Study:
- To review the current landscape of pharmacotherapy for Alzheimer's disease.
- To highlight the significance of newly approved symptomatic treatments and future directions.
Main Methods:
- Literature review of pharmacotherapy for Alzheimer's disease.
- Analysis of the impact of tacrine approval and potential future therapies.
Main Results:
- Tacrine, a symptomatic therapy, has been approved and demonstrates cognitive benefits for some Alzheimer's disease patients.
- The development of similar symptomatic therapies is expected in the near future.
Conclusions:
- Symptomatic pharmacotherapy represents a significant advancement in Alzheimer's disease management.
- Long-term strategies for Alzheimer's disease prevention and cure will rely on understanding its underlying pathogenesis, including genetic factors.